APOE and Alzheimer disease: PRS+ and APOE4+ participants had 3.40 (95%CI: 2.28–5.09) and 3.34 (95% CI: 2.24–4.99) times the odds of developing AD within 17 years than PRS- and APOE-participants, respectively (Table 2).